Previous Article | Next Article ![]()
Molecular and Cellular Biology, December 2002, p. 8409-8414, Vol. 22, No. 24
0270-7306/02/$04.00+0 DOI: 10.1128/MCB.22.24.8409-8414.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Department of Life Science, Pohang University of Science and Technology, Pohang 790-784,1 School of Biological Sciences and Department of Microbiology, Seoul National University, Seoul 151-742,2 Samsung Biomedical Research Institute,3 Molecular Therapy Research Center, Samsung Medical Center, Seoul 135-710,5 Department of Medicine,6 Department of Ophthalmology,7 Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon 440-746, Korea4
Received 19 April 2002/ Returned for modification 2 August 2002/ Accepted 17 September 2002
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
ASC-2, also named AIB3, TRBP, RAP250, NRC, and PRIP, is a recently isolated transcriptional coactivator molecule which is gene amplified and overexpressed in human cancers and stimulates transactivation by nuclear receptors, AP-1, NF-
B, SRF, and numerous other transcription factors (1, 10-12, 14, 24). In particular, the single-cell microinjection results with ASC-2 antibody demonstrated that endogenous ASC-2 is required for transactivation by nuclear receptors and AP-1 (11, 12). More recently, ASC-2 was found to exist in a steady-state complex of approximately 2 MDa that contains histone H3-lysine 4-specific methyltransferase enzymes, and chromatin immunoprecipitation experiments demonstrated that this complex specifically binds to the retinoid-responsive ß-retinoic acid response element and p21WAF1 promoter regions in a ligand-dependent manner (Goo et al., unpublished data).
Interestingly, ASC-2 contains two nuclear receptor interaction domains (12), both of which are dependent on the integrity of their core LXXLL sequences (16, 19). The C-terminal LXXLL motif specifically interacts with the liver X receptors (LXR
and LXRß), whereas the N-terminal motif binds a broad range of nuclear receptors (12).
In this report, we show that inhibition of ASC-2 recruitment to nuclear receptors by using a dominant negative fragment of ASC-2 encompassing the N-terminal LXXLL motif results in a plethora of developmental and phenotypic abnormalities in mice, including problems with eye, heart, motor activities, and fat metabolism in liver. In particular, the ocular anomaly provides a genetic and histopathological basis for posterior lenticonus with cataract. In addition, our results clearly establish the importance of ASC-2 in nuclear receptor function in vivo.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Single-cell microinjection. Single-cell microinjection was executed as described previously (8). The reporter construct consisted of the ß-retinoic acid response element promoter driving the expression of green fluorescent protein (ß-RARE-GFP). As an indicator construct for microinjection, cytomegalovirus-driven expression vector for red fluorescent protein (CMV-RFP) was used.
Chromatin immunoprecipitation. Primary mouse embryonic fibroblasts (MEF) from wild-type, DN1-transgenic, and DN1/m-transgenic mice were prepared from embryos and cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum. These cells or 293T cells transfected with the DN1 or DN1/m expression vector were treated with 0.1 µM 9-cis-retinoic acid for 40 min. Soluble chromatin from these cells was prepared and immunoprecipitated with the indicated antibodies, as recently described (22). The final DNA extractions were amplified by using a pair of primers that encompass the ß-retinoic acid response element region and generate a 288-bp PCR product. The primers used were 5'-AAGCTCTGTGAGAATCCTG-3' and 5'-GGATCCTACCCCGACGGTG-3'.
Histological examination and immunohistochemistry. Organs were excised, fixed with 10% formaldehyde, embedded in paraffin, sectioned in 4-µm slices and stained with hematoxylin and eosin as described previously (21). The organs examined were eyes, liver, kidney, heart, lung, spleen, stomach, brain, pituitary gland, gall bladder, and adrenal gland from mouse embryos and postnatal animals.
To measure cellular proliferation in embryonic eyes, pregnant mice were injected intraperitoneally with bromodeoxyuridine (BrdU; Roche) 2 h before necropsy. Embryos were isolated and fixed in 10% formalin. Then 4-µm paraffin sections were blocked in 2.5% bovine serum albumin and incubated with mouse monoclonal antibody against BrdU. After washing in phosphate-buffered saline, sections were incubated with fluorescein isothiocyanate-conjugated anti-mouse immunoglobulin secondary antibody (Pierce) and washed with phosphate-buffered saline containing 4',6'-diamidino-2-phenylindole (DAPI) (Sigma).
| RESULTS AND DISCUSSION |
|---|
|
|
|---|
B (data not shown). Importantly, DN1-mediated repression was recovered by overexpressed ASC-2 but not by two well-characterized LXXLL-type coactivators, SRC-1 and TRAP220 (16, 19) (Fig. 1A). Similar results were also obtained with single-cell microinjections (Fig. 1C).
|
|
To circumvent this potential lethality problem as well as to unravel the nuclear receptor-specific function of ASC-2 among its multitude of in vivo functions, we took an alternative approach to expressing DN1, a dominant negative fragment of ASC-2 in mice. Thus, any phenotype in DN1-expressing transgenic mice not observed with DN1/m-expressing mice should reflect the in vivo function of ASC-2 specific to DN1-interacting nuclear receptors. The ubiquitously active ß-actin promoter was exploited to obtain five independent transgenic founder mouse lines that expressed DN1 in various tissues examined (designated DN1-transgenic). Consistent with the cell-based results, retinoid-dependent recruitment of ASC-2 to the retinoic acid response element from the retinoic acid receptor ß2 promoter was significantly decreased in MEF from DN1-transgenic mice relative to controls, whereas no such effect was observed with TRAP220 (Fig. 2B).
These transgenic mice showed a variety of pathological anomalies in many different organs (Table 1). Importantly, these transgenes were not lethal except for the early death of DN1-transgenic mouse 87 with heart failure (within 2 months after birth). The defects included incomplete septum closure as well as thrombosis and hypertrophy of the left atrium of the heart, unusually swollen pituitary and adrenal glands, impaired motor activities, much smaller spleen, fat-loaded liver, congested and inflammatory lung in which COX-2 expression was strongly induced (data not shown), and eyes with microphthalmia and posterior lenticonus with cataract.
|
gene (9), suggesting that the other heart defects may involve additional nuclear receptors. Interestingly, the phenotypes observed were nicely correlated with the expression patterns and levels of DN1. For instance, the expression level of DN1 in the eye was significantly greater in DN1-transgenic mice 54, 84, and 87 than in DN1-transgenic mice 71 and 104 (Table 1 and Fig. 3A). Accordingly, the former group had either bilateral or unilateral eye defects as well as severe embryonic eye development problems, whereas the latter group exhibited only milder, unilateral defects and no embryonic eye anomalies (Table 1). Similarly, DN1-transgenic mouse 87, which showed the highest expression level of DN1 in the heart, died with heart failure. In contrast, DN1-transgenic mouse 54 showed no defective heart phenotype at all, consistent with the lack of DN1 expression in the heart.
|
Interestingly, all five transgenic lines expressed DN1 protein in their eyes (Table 1 and Fig. 3A) and developed microphthalmia and cataracts (Fig. 3B to E). In addition, histological examination of affected lenses from at least two independent mice (54 and 84 in Table 1) indicated posterior lenticonus with numerous vacuolations (Fig. 3G and L), covered by relatively intact migration of equatorial epithelial cells (Fig. 3I) but defective posterior lens capsule (Fig. 3K) in 2-month-old adult mice. Posterior lenticonus is known to occur as a sporadic condition, and its etiology has been widely debated due to the rare occurrence of this condition and the difficulties in obtaining clinical samples (4). However, its possible pathogenic causes have been speculated to include overgrowth of posterior lens fibers, uneven pull on the zonules during embryogenesis, and hyaloid artery traction.
In our DN1-transgenic animals, detailed serial sections of the eyes revealed a persistent connection between the optic nerve and projected posterior segment (Fig. 3M and N). Furthermore, DN1-transgenic mouse retinas exhibited marked disorganization of cellular layer patterns of the neural retina (Fig. 3O and P). From these results, we suggest that posterior lenticonus with cataract derives from persistent traction between the optic nerve and posterior segment of the lens, resulting in rupture or protrusion of a weak and thin part of the posterior lens capsule.
It should be noted that posterior lenticonus is responsible for a significant portion of childhood cataracts, implying congenital or early-onset defects (20). With our DN1-transgenic animals, ocular abnormalities were also observed when newborns opened their eyes, which prompted us to examine their embryonic eye development. Gross anatomical examination of embryonic eyes (Fig. 4A and B) and hematoxylin and eosin staining of eyes from embryonic day 13.5 (E13.5) to E17.5 (Fig. 4C to H) revealed that eyes from DN1-transgenic mice had abnormal lens development. The size of the palpebral fissure was reduced in DN1-transgenic mouse embryo eyes (Fig. 4B), which may explain the absence of eyes in a severe case (Fig. 3Q).
|
Consistent with these results, the near posterior surface of the lens and vitreous cavity region of DN1-transgenic mice showed higher DNA replication rates, as indicated by BrdU incorporation (Fig. 4L and O). Interestingly, this phenotype closely resembles that of persistent hyperplastic primary vitreous (5), a congenital developmental anomaly of human eyes. Taken together, these results further support the hypothesis that traction on the posterior capsule of the lens by remnants of the primary vitreous and the hyaloid vascular system at embryonic stages may cause posterior lenticonus with cataract after birth.
Defect in retinoic acid receptor signaling in DN1-transgenic mice.
Cataract in childhood is caused not only by posterior lenticonus (20) but also by dysregulation or mutation of various crystallin genes, the hallmark of normal lens differentiation (7). The
B and
F crystallin genes were previously shown to contain functional retinoic acid response elements (6, 23). Other
-crystallin genes were also suggested to have putative retinoic acid response elements (13). Indeed, reverse transcription-PCR analyses of RNAs from the eyes of E15.5 wild-type and DN1-transgenic mice (17) showed that the mRNA levels of the
B,
C,
D, and
F crystallin genes were significantly downregulated in DN1-transgenic mice (Fig. 5A). These results newly identified the
C and
D-crystallin genes as functional retinoid-responsive genes. In contrast, expression of other crystallin genes that are not retinoid responsive, notably ßA3/A1, was unaffected. Similarly, transcription of luciferase reporter constructs driven by the retinoid-responsive promoters of the
B and
F crystallin genes (6, 23) was activated by retinoids in cotransfections and was repressed by coexpressed DN1 but not DN1/m (Fig. 5B and data not shown). Reverse transcription-PCR analyses of RNAs from MEF from wild-type and DN1-transgenic mice revealed that the mRNA levels of the retinoid-responsive genes CRBPI and retinoic acid receptor ß2 (3) were compromised in DN1-transgenic mice (Fig. 5C).
|
gene was previously shown to result in development of cataracts and incomplete septum closure in the embryonic heart (9), phenocopying some of the defects observed with our DN1-transgenic mice. In addition, a phenotypic synergy was observed with ocular defects when the retinoid X receptor
mutation was introduced into retinoic acid receptor
or retinoic acid receptor
mutant backgrounds (9). However, it should be noted that the embryonic lethality and functional redundancy in these retinoid X receptor
-deficient mice made it impossible to evaluate ocular defects of the adult stage, such as posterior lenticonus, as described in this report. Overall, our findings strongly suggest that retinoic acid receptor signaling is impaired in DN1-transgenic mice and that the nuclear receptors targeted by DN1 in eye development likely include retinoid receptors.
Our strategy of expressing a specific dominant negative fragment in mice is an excellent alternative to gene targeting approaches, which often result in functional redundancy or early embryonic lethality. More importantly, this approach should facilitate the dissection of a specific function of multifunctional coactivators such as ASC-2, CBP/p300, and SRC-1. As exemplified in this report, DN1-transgenic and DN1/m-transgenic animals enabled us to study the physiological role of ASC-2 with a subset of nuclear receptors that bind the N-terminal LXXLL motif of ASC-2 without complications from a multitude of other nuclear receptors and transcription factors. Similarly, transgenic mouse lines that express another dominant negative fragment of ASC-2 containing the second LXXLL motif, which specifically interacts with the orphan nuclear receptors LXR
and LXRß (12), rapidly accumulated a large amount of cholesterol in the liver (our unpublished results), as expected from the known function of LXRs to stimulate the transcription of genes encoding transporters involved in cholesterol efflux (2).
We conclude that ASC-2 is likely an essential transcriptional coactivator of many nuclear receptors in vivo. Importantly, our studies provide novel insights into the molecular mechanism for the pathogeneses of human posterior lenticonus with cataract (4, 5, 7). Likewise, these mice will prove to be useful as a unique in vivo model for a variety of pathogeneses and diseases that involve ASC-2-interacting nuclear receptors.
| ACKNOWLEDGMENTS |
|---|
This work was supported by grants from Postech Biotech Center (3PD02002) and GenoCheck, Inc. (to J.W.L.) and 21C Frontier Functional Human Genome Project from MOST, NRL (M1-0203-00-0108), KOSEF (SRC-MTRC), and Samsung Biomedical Research Institute (to H.W.L.). C.C. is the recipient of a BK21 Research Fellowship from KME.
The first two authors contributed equally.
| FOOTNOTES |
|---|
| REFERENCES |
|---|
|
|
|---|
2. Chawla, A., J. J. Repa, R. M. Evans, and D. J. Mangelsdorf. 2001. Nuclear receptors and lipid physiology: opening the X-files. Science 294:1866-1870.
3. Chiva, H., J. Clifford, D. Metzger, and P. Chambon. 1997. Distinct retinoid X receptor-retinoic acid receptor heterodimers are differentially involved in the control of expression of retinoid target genes in F9 embryonal carcinoma cells. Mol. Cell. Biol. 17:3013-3020.[Abstract]
4. Gibbs, M. L., M. Jacobs, A. O. Wilkie, and D. Taylor. 1993. Posterior lenticonus: clinical patterns and genetics. J. Pediatr. Ophthalmol. Strabismus 30:171-175.[Medline]
5. Goldberg, M. F. 1997. Persistent fetal vasculature (PFV): an integrated interpretation of signs and symptoms associated with persistent hyperplastic primary vitreous (PHPV). LIV Edward Jackson Memorial Lecture. Am. J. Ophthalmol. 124:587-626.[Medline]
6. Gopal-Srivastava, R., A. Cvekl, and J. Piatigorsky. 1998. Involvement of retinoic acid/retinoid receptors in the regulation of murine
B-crystallin/small heat shock protein gene expression in the lens. J. Biol. Chem. 273:17954-17961.
7. Javitt, J. C., F. Wang, and S. K. West. 1996. Blindness due to cataract: epidemiology and prevention. Annu. Rev. Public Health 17:159-177.[CrossRef][Medline]
8. Jhun, B. H., D. W. Rose, B. L. Seely, L. Rameh, L. Cantley, A. R. Saltiel, and J. M. Olefsky. 1994. Microinjection of the SH2 domain of the 85-kilodalton subunit of phosphatidylinositol 3-kinase inhibits insulin-induced DNA synthesis and c-fos expression. Mol. Cell. Biol. 14:7466-7475.
9. Kastner, P., J. M. Grondona, M. Mark, A. Gansmuller, M. LeMeur, D. Decimo, J. L. Vonesch, P. Dolle, and P. Chambon. 1994. Genetic analysis of retinoid X receptor alpha developmental function: convergence of retinoid X receptor and retinoic acid receptor signaling pathways in heart and eye morphogenesis. Cell 78:987-1003.[CrossRef][Medline]
10. Ko, L., G. R. Cardona, and W. W. Chin. 2000. Thyroid hormone receptor-binding protein, an LXXLL motif-containing protein, functions as a general coactivator. Proc. Natl. Acad. Sci. USA 97:6212-6217.
11. Lee, S. K., S. L. Anzick, J. E. Choi, L. Bubendorf, X. Y. Guan, Y. K. Jung, O. P. Kallioniemi, J. Kononen, J. M. Trent, D. Azorsa, B. H. Jhun, J. H. Cheong, Y. C. Lee, P. S. Meltzer, and J. W. Lee. 1999. A nuclear factor, ASC-2, as a cancer-amplified transcriptional coactivator essential for ligand-dependent transactivation by nuclear receptors in vivo. J. Biol. Chem. 274:34283-34293.
12. Lee, S. K., S. Y. Jung, Y. S. Kim, S. Y. Na, Y. C. Lee, and J. W. Lee. 2001. Two distinct nuclear receptor-interaction domains and CREB-binding protein-dependent transactivation function of activating signal cointegrator-2. Mol. Endocrinol. 15:241-254.
13. Lengler, J., E. Krausz, S. Tomarev, A. Prescott, R. A. Quinlan, and J. Graw. 2001. Antagonistic action of Six3 and Prox1 at the gamma-crystallin promoter. Nucleic Acids Res. 29:515-526.
14. Mahajan, M. A., and H. H. Samuels. 2000. A new family of nuclear receptor coregulators that integrate nuclear receptor signaling through CREB-binding protein. Mol. Cell. Biol. 20:5048-5063.
15. Mangelsdorf, D. J., C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, P. Chambon, and R. M. Evans. 1995. The nuclear receptor superfamily: the second decade. Cell 83:835-839.[CrossRef][Medline]
16. McKenna, N. J., and B. W. O'Malley. 2000. From ligand to response: generating diversity in nuclear receptor coregulator function. J. Steroid Biochem. Mol. Biol. 74:351-356.[CrossRef][Medline]
17. Nishiguchi, S., H. Wood, H. Kondoh, R. Lovell-Badge, and V. Episkopou. 1998. Sox1 directly regulates the gamma-crystallin genes and is essential for lens development in mice. Genes Dev. 12:776-781.
18. Niwa, H., K. Yamamura, and J. Miyazaki. 1991. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108:193-199.[CrossRef][Medline]
19. Rosenfeld, M. G., and C. K. Glass. 2001. Coregulator codes of transcriptional regulation by nuclear receptors. J. Biol. Chem. 276:36865-36868.
20. Russell-Eggitt, I. M. 2000. Non-syndromic posterior lenticonus a cause of childhood cataract: evidence for X-linked inheritance. Eye 14:861-863.[Medline]
21. Serrano, M., H. Lee, L. Chin, C. Cordon-Cardo, D. Beach, and R. A. DePinho. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85:27-37.[CrossRef][Medline]
22. Shang, Y., X. Hu, J. DiRenzo, M. A. Lazar, and M. Brown. 2000. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 103:843-852.[CrossRef][Medline]
23. Tini, M., G. Otulakowski, M. L. Breitman, L. C. Tsui, and V. Giguere. 1993. An everted repeat mediates retinoic acid induction of the gamma F-crystallin gene: evidence of a direct role for retinoids in lens development. Genes Dev. 7:295-307.
24. Zhu, Y., L. Kan, C. Qi, Y. S. Kanwar, A. V. Yeldandi, M. S. Rao, and J. K. Reddy. 2000. Isolation and characterization of peroxisome proliferator-activated receptor (PPAR) interacting protein (PRIP) as a coactivator for PPAR. J. Biol. Chem. 275:13510-13516.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|